Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: A phase II study of the Italian Sarcoma Group (ISG)

Anticancer Research

Volumn 20, Issue 1 B, 2000, Pages 485-491

  Toma, Salvatore ^a   Tucci, Aniello ^b   Villani, Giorgio ^a   Carteni, Giacomo ^b   Spadini, Nicoletta ^c   Palumbo, Raffaella ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Dose intensity; Liposomal doxorubicin; Soft tissue sarcomas

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LIPOSOME;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTENSION; ITALY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SCROTUM; SKIN TOXICITY; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ALOPECIA; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG COMPOUNDING; DRUG ERUPTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; LIFE TABLES; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; REMISSION INDUCTION; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0034109686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dirix LY, van Oosterom AT: Soft tissue sarcoma in adults. Curr Opin Oncol 11: 285-295, 1999.
2. Saeter G: Chemotherapy for adult soft tissue sarcoma: does it work? Acta Orthop Scand 273: 139-144, 1997.
3. Toma S, Palumbo R, Sogno G, Venturino A, Santi L: Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult soft tissue sarcomas. Ann Oncol 3 (Suppl. 2): 119-123, 1992.
4. Toma S, Palumbo R, Canavese G, Albanese E, Cantoni E, Barisone A, Reggiardo G, Rosso R, Santi L: Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Cancer Chemother Pharmacol 31 (Suppl. 2): 222-227, 1993.
5. Casali P, Pastorino U, Azzarelli A, Bertulli R, Zucchinelli P, Devizzi L, Santoro A: Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 31 (Suppl. 2): 228-232, 1993.
6. Demetri GD, Elias AD: Results of single agents and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Sarcomas, Pt. II. Hematol Oncol Clin North Am 9: 765-785, 1995.
7. Bokemeyer C, Franzke A, Hartmann J, Schober C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced Soft tissue sarcomas. Cancer 80: 1221-1227, 1997.
8. Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo Re G, Sorio R, Tumolo S, Monfardini S: Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced Soft Tissue Sarcomas: a pilot study. J Clin Oncol 15: 1418-1426, 1997.
9. Reichardt P, Tilgner J, Hohenberger P, Dorken B: Dose-intensive chemotherapy with Ifosfamide, Epirubicin, and filgastrim for adult patients with metastatic or locally advanced Soft Tissue Sarcoma: a phase II study. J Clin Oncol 16: 1438-1443, 1998.
10. Leyvraz S, Bacchi M, Cerny T, Lissoni A, Sessa C, Bressoud A, Hermann R: Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 9: 877-884, 1998.
11. Palumbo R, Neumaier C, Cosso M, Bertero G, Raffo P, Spadini N, Valente S, Villani G, Pastorino M, Toma S: Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft Tissue Sarcomas: a phase II study. Eur J Cancer 35: 66-72, 1999.
12. Edmonson JK, Ryan LM, Blum RH, Brooks JS, Shiraki M, Grytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993.
13. Edmonson JH: Needed: qualitative improvement in antisarcoma therapy. J Clin Oncol 13: 1531-1533, 1997.
14. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, Van Glabbeke M, van Oosterom: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced Soft Tissue Sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545, 1995.
15. Gortzak E, van Coevorden F: Soft tissue sarcoma - Messages from completed randomsied trials. Eur J Surg Oncol 21: 469-477, 1995.
16. Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840-850, 1987.
17. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzack SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940-1948, 1977.
18. Pinedo HM, Bramwell VH, Mouridsen HT, Somers R, Vendrik CP, Santoro A, Buesa J, Vagener T, van Oosterom AT, van Unnik JA: CYVADIC in advanced soft-tissue sarcoma - A randomized study comparing two schedules. A study of the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer 53: 1825-1832, 1984.
19. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat O, Clavel M, Crowther D, Rousse J, Tursz T, Tueni E: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcoma: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11: 15-21, 1993.
20. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z: Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42: 4734-4739, 1982.
21. Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P, Schein PS: Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 40: 1532-1537, 1980.
22. O'Days SJ, Mazanet R, Skarin AT, Salgia R, Gordon D, Elias AD: Dose escalation of liposome-encapsulated doxorubicin (D-99) with granulocyte colony stimulating factor (G-CSF) support in patients with advanced malignancies. Proc Am Soc Clin Oncol 13: 153, 1994 (abstract).
23. Skubitz KM: Early results of a phase II study of liposomal doxorubicin (Doxil) in refractory sarcoma. Proc Am Soc Clin Oncol 16: 508, 1997 (abstract).
24. Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF: Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15: 2111-2117, 1997.
25. Elson P, Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Crownover R, Marks K, Muschler C, Zher R, Joyce M, Bukowski R: Phase II trial of doxil in advanced soft tissue sarcomas (STS) (abstract). Proc Am Soc Clin Oncol 17: 513, 1998 (abstract).
26. Garcia AA, Kempf RA, Rogers M, Muggia FM: A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 9: 1131-1133, 1998.
27. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48. Geneva, Switzerland, WHO, 1979.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
29. Toma S, Tucci A, Villani G, Carteni G, Palumbo R: Liposomal doxorubicin (Caelyx) in advanced pretreated Soft Tissue Sarcomas (STS): a phase II trial of the Italian Sarcoma Group (ISG). Proc Am Soc Clin Oncol 18: 540, 1999 (abstract).
30. Judson I, Radford J, Blay JY, van Hoesel Q, Le Cesne A, van Oosterom A, Nielsen OS, Kamhy C, Woll P, Harris M, Hermans C, Donato di Paola E, Verweij J: A randomized phase II trial of Caelyx/Doxil versus doxorubicin in advanced or metastatic Soft Tissue Sarcomas (STS)-An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial. Proc Am Soc Clin Oncol 18: 541, 1999 (abstract).
31. Skubitz KM: A phase II trial of Pegylated Liposomal Doxorubicin (Doxil) demonstrates activity in refractory sarcoma, mesothelioma, and head and neck cancer. Proc Am Soc Clin Oncol 18: 541, 1999 (abstract).
32. Reichardt P, Verweij J, Crowther D: Should high-dose chemotherapy be used in the treatment of Soft Tissue Sarcoma? Eur J Cancer 33: 1351-1360, 1997.
33. Elias AD: High-dose therapy for adult Soft Tissue Sarcomas: dose response and survival. Semin Oncol 25: 19-23, 1998.
34. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, Vilian MO, Jacquemier J, Duplay H, Sastre X, Barlier C, Henry-Amar M, Macß-Lesech J, Contesso G: Prognostic factors in adult patients with locally controlled Soft Tissue Sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14: 869-877, 1946.
35. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Turs T: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17: 150-157, 1999.
36. Wiklund T, Saeter G, Strander H, Alvegard T, Blomqvist C: The outcome of advanced Soft Tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group Experience. Eur J Cancer 33: 357-361, 1997.